BOSTON--(BUSINESS WIRE)--GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced that CEO Daniel J. Mandell, PhD has been named to the Class of 2023 Termeer Fellows.
The Henri Termeer Fellowship Program was created in honor of the late Henri Termeer – a visionary leader in the biotechnology industry – and is designed to support first-time CEOs who are patient-focused and working passionately to address unmet medical needs through innovative science. Termeer Fellows are supported through mentoring, networking, and professional development intended to foster growth in leadership for rising healthcare leaders working to solve the most difficult challenges in medicine.
The Henri Termeer Fellowship program “has focused on supporting and mentoring the next generation of biotech entrepreneurs. We have done this with a rigorous interview process to select Termeer Fellows each year that have the same values and passion to make a difference and carry forward Henri’s legacy,” Termeer Foundation President Belinda Termeer said in the foundation’s announcement.
“I would like to thank the Termeer Foundation for naming me to the Class of 2023 Termeer Fellows. I am truly honored to be counted among this year’s cohort of biotech entrepreneurs recognized by the foundation as furthering the values and mission of Henri Termeer. I look forward to growing as a leader through this incredible network of innovators and mentors,” commented Dr. Mandell.
Learn more about The Termeer Foundation and their dedication to connecting the world of healthcare innovators until every patient has a cure by visiting their website.
About GRO Biosciences
GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments in diverse areas including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique non-standard amino acid (NSAA) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including precise regulation of the immune system and unprecedented duration of action. GRObio is headquartered in Cambridge, MA.